Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRPK1 | Q96SB4 | 3/20 | 0.69 |
| ▸ | KDR | P35968 | 2/20 | 0.69 |
| ▸ | SRPK2 | P78362 | 1/20 | 0.69 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.69 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TEK | Q02763 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485991 | 1.00 | SRPK1 (0.69) | SRPK1KDRSRPK2SRPK3GPBAR1 | |
| SCHEMBL20554756 | 0.88 | SRPK1 (0.69) | SRPK1KDRSRPK2SRPK3POLB | |
| SCHEMBL22700668 | 0.88 | KDR (0.51) | SRPK1KDRSRPK2SRPK3GPBAR1 | |
| SCHEMBL1110821 | 0.86 | SRPK1 (0.66) | SRPK1KDRSRPK2SRPK3POLB | |
| SCHEMBL1110819 | 0.86 | SRPK1 (0.66) | SRPK1KDRSRPK2SRPK3POLB | |
| SCHEMBL1110816 | 0.86 | SRPK1 (0.66) | SRPK1KDRSRPK2SRPK3POLB | |
| SCHEMBL12855743 | 0.86 | SRPK1 (0.66) | SRPK1KDRSRPK2SRPK3POLB | |
| SCHEMBL3485920 | 0.82 | SRPK1 (0.98) | SRPK1KDRSRPK2SRPK3POLB | |
| SCHEMBL1110544 | 0.82 | SRPK1 (1.00) | SRPK1KDRSRPK2SRPK3POLB | |
| SCHEMBL1110476 | 0.82 | SRPK1 (1.00) | SRPK1KDRSRPK2SRPK3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210100781-A1 | TUMOR SUPPRESSION | KYOTO UNIVERSITY (JP) | 2021-04-08 | — | — | US | disclosed |
| EP-2666481-B9 | Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient | HAGIWARA MASATOSHI (JP) | 2019-05-22 | — | — | EP | disclosed |
| EP-2666481-B1 | Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient | HAGIWARA MASATOSHI (JP) | 2018-11-14 | — | — | EP | disclosed |
| EP-1712242-B1 | METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT | HAGIWARA MASATOSHI (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-8816089-B2 | Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity | Hagiwara, Masatoshi (JP) | 2014-08-26 | — | — | US | disclosed |
| CN-101837125-B | Method of regulating phosphorylation of PTH protein and antiviral agents comprising SR protein activity regulator as the active ingredient | HAGIWARA MASATOSHI | 2014-02-26 | — | — | CN | disclosed |
| EP-2666481-A2 | Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient | HAGIWARA, Masatoshi (JP) | 2013-11-27 | — | — | EP | disclosed |
| CN-1921885-B | Use of an aniline derivative or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a viral infection in a patient | HAGIWARA MASATOSHI | 2013-06-12 | — | — | CN | disclosed |
| US-20130079369-A1 | METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY | Hagiwara, Masatoshi (JP) | 2013-03-28 | — | — | US | disclosed |
| US-8338362-B2 | Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity | MASATOSHI HAGIWARA (JP) | 2012-12-25 | — | — | US | disclosed |
| US-8338362-B2 | Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity | MASATOSHI HAGIWARA (JP) | 2012-12-25 | — | — | US | disclosed |
| CN-101837125-A | The proteinic phosphorylation control method of SR and be the antiviral agent of effective ingredient with the reagent that comprises the SR protein activity regulator | MASATOSHI HAGIWARA | 2010-09-22 | — | — | CN | disclosed |
| US-20100016359-A1 | METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY | MASATOSHI HAGIWARA | 2010-01-21 | — | — | US | disclosed |
| US-20100016359-A1 | METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY | MASATOSHI HAGIWARA | 2010-01-21 | — | — | US | disclosed |
| US-7569536-B2 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | Hagiwara, Masatoshi (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20070135367-A1 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | HAGIWARA, MASATOSHI (JP) | 2007-06-14 | — | — | US | disclosed |
| CN-1921885-A | Method for controlling phosphorylation of SR protein and antiviral agent comprising SR protein activity controller as active ingredient | HAGIWARA MASATOSHI (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1712242-A1 | METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT | HAGIWARA, Masatoshi (JP) | 2006-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079369-A1 | METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY | SRPK1, SRPK3, SRPK2 | SRPK1 1/4885KDR 4350/4885SRPK2 3/4885 |
| US-20070135367-A1 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | SRPK1, SARS1, SRPK3 | SRPK1 1/4885KDR 2410/4885SRPK2 4/4885 |
| US-20100016359-A1 | METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY | SRPK1, SRPK3, SRPK2 | SRPK1 1/4885KDR 4350/4885SRPK2 3/4885 |
| US-20210100781-A1 | TUMOR SUPPRESSION | TSG101, TP53, VHL | SRPK1 1293/4885KDR 3702/4885SRPK2 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.